Liver Failure
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Liver Failure is an emerging landscape with 12 programs across 9 companies. The most active players are Takeda, AstraZeneca, Johnson & Johnson. 5 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Takeda
1 program
AstraZeneca
1 program
Johnson & Johnson
1 program
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 program
BioCorRx Pharmaceuticals Inc
1 program
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
87%
Small molecule
13 of 15 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.
Analysis
Trial Status
13
clinical trials
Clinical Trials
Trial Activity
13 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)